A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

NCT03927456 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

357

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: SHR6390
DRUG: Placebo
DRUG: Fulvestrant

Sponsor

Jiangsu HengRui Medicine Co., Ltd.